Everolimus: A new hope for patients with breast cancer

Current Medical Research and Opinion

Volumn 30, Issue 1, 2014, Pages 75-87

  Sendur, Mehmet A N ^a   Zengin, Nurullah ^a   Aksoy, Sercan ^b   Altundag, Kadri ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Endocrine therapy resistance; Everolimus; MTOR pathway; Trastuzumab resistance

Indexed keywords

AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; HEMOGLOBIN; KI 67 ANTIGEN; LETROZOLE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ASIAN; BLOOD TOXICITY; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE EFFECTIVENESS; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECHOMAMMOGRAPHY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; GENE LOSS; GERIATRIC PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RECEPTOR, ERBB-2; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84890545412     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.846253     Document Type: Review

References (82)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
2. Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: Analysis using population-based SEER registries. J Natl Cancer Inst 2009;101:533-6
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717
5. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92
6. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol 2010;28:3366-79
7. Colozza M, de Azambuja E, Cardoso F, et al. Breast cancer: Achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006;11: 111-25
8. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: Implications for human breast cancer. Oncogene 2007;26:1338-45
9. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclindependent kinase modulators. J Natl Cancer Inst 2000;92:376-87
10. Liedtke C, Cardone L, Tordai A, et al. PIK3CA-Activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 2008;10:R27
11. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81
12. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007;13:3577-84
13. Meric-Bernstam F, Esteva FJ. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy. Clin Breast Cancer 2005;6:357-60
14. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58
15. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402
16. Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004;10:6779-88
17. Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-42
18. O'Donnell A, Faivre S, Burris 3rd HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26:1588-95
19. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
20. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide longacting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebocontrolled, phase 3 study. Lancet 2011;378:2005-12
21. Zagouri F, Sergentanis TN, Chrysikos D, et al. mTOR inhibitors in breast cancer: A systematic review. Gynecol Oncol 2012;127:662-72
22. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giantcell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
23. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
24. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
25. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43
26. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutionalbased review. J Clin Oncol 2010;28:92-8
27. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
28. Margariti N, Fox SB, Bottini A, Generali D. 'Overcoming breast cancer drug resistance with mTOR inhibitors'. Could it be a myth or a real possibility in the short-Term future? Breast Cancer Res Treat 2011;128:599-606
29. Lu CH, Wyszomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-8
30. Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-65
31. DeGraffenried LA, Fulcher L, Friedrichs WE, et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004;15:1510-16
32. Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8
33. Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res 2007;138:37-44
34. Ghayad SE, Bieche I, Vendrell JA, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 2008;99:1992-2003
35. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28
36. Cottu PH, Bagarre T, Assayag F, et al. Targeting the PI3K/mTOR pathway in patient-derived xenograft models of endocrine resistant luminal breast cancer. Cancer Res 2012;72(24 Suppl):498s
37. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429-34
38. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253-60
39. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672-6
40. Yunokawa M, Koizumi F, Kitamura Y, et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 2012;103:1665-71
41. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91
42. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;28:5110-15
43. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-Treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011;125:447-55
44. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011;29:3126-32
45. Moulder S, Gladish G, Ensor J, et al. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 2012;118:2378-84
46. Schwarzlose-Schwarck S, Scholz CW, Regierer AC, et al. The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer-A phase I trial. Anticancer Res 2012;32:3435-41
47. Mayer IA, Means-Powell J, Shyr Y, Arteaga CL. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. 2009 Breast Cancer Symposium 2009
48. Mayer IA, Means-Powell J, Shyr Y. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, abstract 3094, 2009
49. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536-41
50. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-24
51. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
52. Mayer IA, Means-Powell J, Abramson VG, et al. Phase II trial of RAD001 (everolimus), an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 2011;71(24 Suppl):151s
53. Singh JC, Volm M, Novik Y, et al. A Phase 2 trial of RAD 001 and carboplatin in patients with triple negative metastatic breast cancer. Cancer Res 2012;72(24 Suppl):480s
54. Gonzalez-Angulo AM, Green MC, Murray JL, et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). J Clin Oncol 2011;29(Suppl):Abstract 1016
55. Safra T, Kaufman B, Ben Baruch N, et al. RAD001 (everolimus) in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer after failure of hormonal therapy-A phase II study. Cancer Res 2012;72(24 Suppl):480s
56. Piccart M, Baselga J, Noguchi S, et al. Final progression-free survival analysis of BOLERO-2: A phase III trial of everolimus for postmenopausal women with advanced breast cancer. Cancer Res 2012;72(24 Suppl):492s
57. Rugo HS, Burris HA III, Gnant M, et al. Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. J Clin Oncol 2012;30(Suppl 27):Abstract 104
58. Noguchi S, Masuda N, Iwata H, et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormonereceptor-positive breast cancer in BOLERO-2. Breast Cancer. Feb 13 2013 [Epub ahead of print
59. Burris 3rd HA, Lebrun F, Rugo HS, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013;119:1908-15
60. Gnant M, Baselga J, Rugo HS, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 2013;105:654-63
61. Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)/-bevacizumab-results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013;49: 2284-93
62. O'Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol 2013;31(Suppl):Abstract 505
63. Hurvitz SA, Andre F, Burris HA, et al. BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2), locally advanced or metastatic breast cancer (BC). J Clin Oncol 2012;30(Suppl):Abstract TPS648
64. Gradishar WJ, Bachelot TD, Saletan S, et al. BOLERO-4: Multicenter, openlabel, phase II study of everolimus plus letrozole as first-line therapy in ER, HER2-metastatic breast cancer. J Clin Oncol 2013;31(Suppl):Abstract TPS661
65. Ejlertsen B, Jerusalem GHM, Hurvitz SA, et al. BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR, HER2-Advanced breast cancer. J Clin Oncol 2013;31(Suppl): Abstract TPS660
66. Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (VicTORia). ClinicalTrials.gov identifier: NCT01520103. Available at: Www.clinicaltrials.gov [Last accessed 13 June 2012
67. Croley JJ, Black EP, Romond E, et al. A phase II study of combined fulvestrant and RAD001 (everolimus) in metastatic estrogen receptor (ER) positive breast cancer after aromatase inhibitor (AI) failure. Cancer Res 2012; 72(24 Suppl):281s
68. A phase III trials program exploring the integration of bevacizumab, everolimus (RAD001), and lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer (GeparQuinto). ClinicalTrials.gov identifier: NCT00567554. Available at: Www.clinicaltrials.gov [Last accessed 11 July 2012
69. Chavez-Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, et al. A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy-one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and HER2-negative breast cancer: SWOG/ NSABP S1207. Cancer Res 2012;72(24 Suppl):570s
70. Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006;8:394-401
71. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22
72. Baselga J, Roche H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: A randomized, 3-Arm, phase 2 study. Breast Cancer Res Treat 2005;94(Suppl 1):S62
73. Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebocontrolled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202
74. Yardley DA. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: Rationale, clinical experience, and future directions. Breast Cancer (Auckl) 2013;7:7-22
75. Bhattacharyya GS, Biswas J, JK S, et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. European Multidiscliplinary Cancer Congress, Edition Stockholm, Sweden, 2011
76. Stokman MA, Spijkervet FK, Boezen HM, et al. Preventive intervention possibilities in radiotherapy-And chemotherapy-induced oral mucositis: Results of meta-Analyses. J Dent Res 2006;85:690-700
77. Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287-98
78. Peddi PF, Shatsky RA, Hurvitz SA. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev. Aug 14 2013 [Epub ahead of print
79. Albiges L, Chammings F, Duclos B, et al. Incidence and management of mTOR inhibitor-Associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:1943-53
80. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62: 299-307
81. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007;39:397-408
82. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83